Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for <i>Mycobacterium tuberculosis</i>
作者:Kathryn M. Nelson、Kishore Viswanathan、Surendra Dawadi、Benjamin P. Duckworth、Helena I. Boshoff、Clifton E. Barry、Courtney C. Aldrich
DOI:10.1021/acs.jmedchem.5b00391
日期:2015.7.23
development. 5′-O-[N-(Salicyl)sulfamoyl]adenosine (1) is a bisubstrate inhibitor of MbtA and exhibits exceptionally potent biochemical and antitubercular activity. However, 1 suffers from suboptimal drug disposition properties resulting in a short half-life (t1/2), low exposure (AUC), and low bioavailability (F). Four strategies were pursued to address these liabilities including the synthesis of prodrugs
MbtA催化分枝杆菌素的第一个重要的生物合成步骤,这是与结核分枝杆菌中铁摄入有关的重要毒力因子。MbtA是抗结核药物开发的经过验证的治疗靶标。5'- O- [ N-(水杨基)氨磺酰基]腺苷(1)是MbtA的双底物抑制剂,具有极强的生化和抗结核活性。然而,1的药物处置特性欠佳,导致半衰期短(t 1/2),低暴露(AUC)和低生物利用度(F)。采取了四种策略来解决这些问题,包括前药的合成,增加酰基磺酰基部分的p K a,调节亲脂性以及将氟引入1的策略。对所有化合物进行了完整的药代动力学(PK)分析。最成功的修饰涉及核苷的氟化,这可显着改善t 1/2和AUC。增加酰基-磺酰基接头的p K a会产生增量的增强,而亲脂性和前药方法的调节则导致PK参数大大降低。